Physician profile
Michael Rubinstein
NPI 1083702633
$1,422.27
in general payments reported to CMS, 2019-2025
20 companies · $32.85 in 2025
The $32.85 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,240 · 2020: $35.42 · 2021: $36.69 · 2022: $30.12 · 2024: $46.79 · 2025: $32.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $187.87 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.86 | 2019 | |
| Amarin Pharma, INC. | $131.72 | 2019 | |
| Merck Sharp & Dohme LLC | $95.68 | 2019 | |
| Pfizer INC. | $91.28 | 2019 | |
| Sanofi-Aventis U.S. LLC | $91.11 | 2019 | |
| Allergan, INC. | $77.98 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $71.70 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $60.74 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $60.45 | 2024-2025 | Eliquis |
| Lilly USA, LLC | $59.06 | 2019 | |
| Abbvie INC. | $56.69 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $46.36 | 2019 | |
| Amgen INC. | $40.15 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $37.36 | 2019 | |
| Abbott Laboratories | $19.19 | 2025 | Freestyle Libre 3 |
| Aytu Biopharma, INC. | $14.41 | 2019 | |
| Glaxosmithkline, LLC. | $14.15 | 2019 | |
| Shionogi INC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.